Dr. Joe O'Sullivan on Utilizing Radium-223 Treatment Earlier in Patients With mCRPC

December 2, 2015
Joe O'Sullivan, MD

Joe O'Sullivan, MD, on utilizing radium-223 treatment earlier in patients with metastatic castration-resistant prostate cancer (mCRPC).

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry, and Biomedical Sciences, Centre for Cancer Research and Biology, Northern Ireland Cancer Centre, on utilizing radium-223 treatment earlier in patients with metastatic castration-resistant prostate cancer (mCRPC). O'Sullivan says that waiting too long to employ radium-223 treatment would not yield the same effects as it would earlier on in the disease.

O'Sullivan also says that in his practice, he combines radium-223 with external beam radiation. He says in the future, and thanks to the international early access program (EAP), radium-223 may be used in combination with other bone-related treatments for added results.